BSI 712
Alternative Names: BSI-712Latest Information Update: 14 Feb 2024
At a glance
- Originator Biosion
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 03 Jul 2023 Biosin announces intention to submit IND application for Solid tumours in 2H 2024 (Biosion pipeline, July 2023)
- 14 Feb 2023 BSI 712 is available for licensing as of 14 Feb 2023. https://www.biosion.com/partnership (Biosion pipeline, February 2023)